Literature DB >> 6696702

Side effects of antimotion sickness drugs.

C D Wood, J E Manno, B R Manno, H M Redetzki, M Wood, W A Vekovius.   

Abstract

The possible influence on operational proficiency of the side effects of the anti-motion sickness drugs was investigated using a computerized pursuit meter as the test device. The medications and doses tested were scopolamine (Hyoscine) 0.25 mg and 0.50 mg oral doses, promethazine (Phenergan) 25 mg oral and 25 mg I.M. doses. Combinations of promethazine 25 mg with 10 mg d-amphetamine (Dexadrine) oral were also used, as was a combination of promethazine 25 mg oral with promethazine 25 mg I.M. and 10 mg of oral d-amphetamine. The proficiency on the pursuit meter task was not significantly altered by 0.25 mg or 0.50 mg doses of scopolamine. The combination of promethazine 25 mg oral with 10 mg d-amphetamine did not produce a significant decrement of performance. When promethazine 25 mg was given as an oral or I.M. dose without amphetamine the decrement of performance was significant and was approximately equivalent to an alcohol blood level of 25-50 mg% (one-two drinks). When a combination of promethazine 25 mg oral plus promethazine 25 mg I.M. with 10 mg d-amphetamine was tested, the error scores were significantly lower than with the oral or I.M. dose of promethazine. This combination also produced an error score significantly higher than placebo level. Promethazine by the I.M. route was slowly absorbed and 6 of the 10 subjects reported drowsiness at 6 h post injection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6696702

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  4 in total

1.  The relation of motion sickness to the spatial-temporal properties of velocity storage.

Authors:  Mingjia Dai; Mikhail Kunin; Theodore Raphan; Bernard Cohen
Journal:  Exp Brain Res       Date:  2003-05-29       Impact factor: 1.972

Review 2.  Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.

Authors:  Zohar Nachum; Avi Shupak; Carlos R Gordon
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Widespread hyoscine hydrobromide toxicity due to contract manufacturer malpractice : the travacalm episode.

Authors:  John McEwen; Barry R Thompson; Patrick M Purcell; Larry F Kelly; Adrian S Krauss
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance.

Authors:  A C Parrott
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.